Abstract
Brain disorders represent 32% of the global disease burden, with 169 million Europeans affected. Constraint-based metabolic modelling and other approaches have been applied to predict new treatments for these and other diseases. Many recent studies focused on enhancing, among others, drug predictions by generating generic metabolic models of brain cells and on the contextualisation of the genome-scale metabolic models with expression data. Experimental flux rates were primarily used to constrain or validate the model inputs. Bi-cellular models were reconstructed to study the interaction between different cell types. This review highlights the evolution of genome-scale models for neurodegenerative diseases and glioma. We discuss the advantages and drawbacks of each approach and propose improvements, such as building bi-cellular models, tailoring the biomass formulations for glioma and refinement of the cerebrospinal fluid composition.
Reference148 articles.
1. GBDCompareDataVisualization. Seattle, WA: IHME, University of Washington
Http://Vizhub.Healthdata.Org/Gbd-Compare
2. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
3. The Burden of Health Care Costs for Patients With Dementia in the Last 5 Years of Life
4. Government’s Missed Opportunity on Research Funding Leaves Dementia Community Disappointed
https://www.alzheimersresearchuk.org/blog/governments-missed-opportunity-on-research-funding-leaves-dementia-community-disappointed/
5. Fact Sheet Cancer
Https://Www.Who.Int/News-Room/Fact-Sheets/Detail/Cancer
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献